Supplementary Table S6 from Association Between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer

Supplementary Table S6. Association between skin or endocrine disorder irAEs and predictors of ICI effect a Mann–Whitney U Test. b Patients who had progression within 4 or 6 weeks after the initiation of treatment were excluded. Abbreviations: CRP, C-reactive protein; ICI, immune checkpoint inhibitor; IHC, immunohistochemical; irAE, immune-related adverse event; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed death ligand-1; Q, quartile; SD, standard deviation.